ASTRA and its associated studies, CIPHER and AURAH, present independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research funding scheme (RP-PG-0608-10142).

The studies were some of the components of CAPRA, a programme for the Comprehensive Assessment of the Prevention Role of Antiretroviral therapy.

The studies also received support through the Comprehensive Clinical Research Network.

This website is provided courtesy of University College London.

UCL Logo

About ASTRA, CIPHER and AURAH

ASTRA was one of the component studies of a research programme which aimed to assess whether a policy of offering antiretroviral therapy (ART) treatment to all people diagnosed with HIV in the UK would be acceptable, effective and cost-effective. The programme was called CAPRA, a programme for the Comprehensive Assessment of the Prevention Role of Antiretroviral therapy.

This site provides information on ASTRA and two of its associated studies, CIPHER and AURAH:

  • ASTRA was a questionnaire study which aimed to assess sexual risk behaviours, beliefs about HIV transmission risk, and attitudes to use of early antiretroviral treatment, in patients with HIV in the UK.
  • CIPHER was based on a subset of the patients who have answered the ASTRA questionnaire and it aimed to assess any HIV associated changes to neurocognitive functioning and their impact on risk behaviours.
  • AURAH was a questionnaire study based on ASTRA which assessed sexual risk behaviour, attitudes to HIV transmission and antiretroviral treatment in HIV-negative individuals at risk of HIV-infection recruited from sexual health clinics.

The CAPRA programme of work also involved

CAPRA was overseen by an Advisory Board, whose members were:

  • Sir Nick Partridge
  • Kay Orton
  • Anthony Nardone
  • Ann Sullivan